Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Prime Medicine, Inc. is set to present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, highlighting its commitment to innovative genetic therapies [1] Company Overview - Prime Medicine is a biotechnology company focused on developing a new class of one-time curative genetic therapies using its proprietary Prime Editing platform, which allows for precise and efficient gene editing [3] - The Prime Editing technology aims to make accurate edits within genes while minimizing unwanted DNA modifications, potentially addressing a wide range of genetic mutations across various tissues and organs [3] Therapeutic Programs - The company is advancing a diversified portfolio of investigational therapeutic programs centered on liver, lung, immunology, and oncology [4] - Prime Medicine is initially targeting high-value programs with well-understood biology and clear clinical development paths, with plans to expand into additional opportunities over time [4] - The company aims to leverage the broad therapeutic potential of Prime Editing to address genetic diseases, immunological diseases, cancers, infectious diseases, and genetic risk factors in common diseases, impacting millions of people [4]